查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1877398

視網膜色素變性（RP）市場：依給藥途徑、診斷、治療類型、疾病類型、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

Retinitis Pigmentosa (RP) Market, By Route of Administration, By Diagnosis, By Treatment Type, By Disease Type, By End-Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年視網膜色素變性 (RP) 市場規模價值為 147.899 億美元，從 2025 年到 2032 年以 7.4% 的複合年成長率成長。

視網膜色素變性（RP）是一組遺傳性視網膜疾病，會損傷視網膜（眼球後部的感光組織），導致進行性視力喪失。 RP患者通常會出現夜視能力下降、周邊視野逐漸喪失，晚期則完全失明。 RP市場的主要驅動力是遺傳性視網膜疾病診斷水平的提高、基因檢測的普及以及基因治療、幹細胞治療和光遺傳學等技術的快速發展，這些技術使得更具針對性和個性化的治療方案成為可能。然而，基因治療的高昂成本以及Luxturna之外獲批療法的匱乏限制了市場成長。關鍵的市場趨勢包括對基於AAV和CRISPR的治療平台的投資增加，以及對早期基因篩檢的日益重視。

視網膜色素變性（RP）市場－市場動態

醫療保健支出不斷成長推動了視網膜色素變性市場的發展

預計醫療保健支出的成長將推動視網膜色素變性市場的未來成長。醫療保健支出是指在特定時期內用於醫療保健產品和服務（例如醫療、藥物、住院和預防性護理）的總金額，反映了特定人群醫療保健服務的總成本。隨著先進醫療技術成本的上升、人口老化以及慢性病的盛行率增加，醫療保健支出也不斷增加。視網膜色素變性的醫療保健支出主要集中在改進診斷方法、開發有效療法以及提供支持性護理以控制視力喪失。例如，根據美國國立衛生研究院（NIH）的數據，2022年美國醫療保健支出成長了4.1%，達到4.5兆美元，成長率高於2021年的3.2%。因此，不斷上漲的醫療保健成本正在推動視網膜色素變性行業的成長。

視網膜色素變性（RP）市場區隔分析：

全球市場按給藥途徑、診斷、治療類型、疾病類型、最終用戶和地區進行細分。

在治療類型細分市場中，基因治療預計將在整個預測期內保持關鍵成長動力。視網膜色素變性的基因治療專注於將功能基因導入患者細胞，以對抗致病突變。 Luxturna（voretigene neparvovec-rzyl）是目前唯一獲得FDA批准用於治療雙等位基因RPE65突變的療法，它能夠恢復視網膜細胞中的功能性基因表現。除Luxturna外，還有多個候選藥物正在臨床試驗中取得進展，這些藥物利用AAV和其他載體技術來靶向更廣泛的突變。領先生物製藥公司的持續投資正在推動研發活動，並塑造該細分市場的上升趨勢。例如，2025年5月，Beacon Therapeutics Holdings Limited公佈了其主要候選藥物laru-zova（laruparetigene zovaparvovec）治療X連鎖視網膜色素變性（XLRP）患者的II期DAWN試驗的6個月中期安全性和有效性結果。

根據治療類型分類，維生素A補充劑仍然是視網膜色素變性（RP）市場中至關重要且具有歷史意義的組成部分，因為維生素A（特別是棕櫚酸視黃酯）長期以來一直被研究用於延緩部分RP患者的感光細胞退化。由於目前尚無廣泛核准的基因療法（針對多種基因亞型），維生素A提供了相對簡單、低技術的補充劑，可延緩視網膜功能的衰退。由於RP具有遺傳異質性，維生素A等營養干預措施為患者提供了一種低成本、可擴展的選擇，尤其是在缺乏先進療法或作為輔助治療手段的情況下。維生素A補充劑表明，即使在以先進療法為主導的市場中，更傳統的非基因療法仍然是治療方案的一部分。據美國國家眼科研究所（NEI）稱，該研究所資助的一項試驗（1984-1992年）發現，每日服用15,000國際單位（IU）的棕櫚酸視黃酯可以減緩視網膜功能衰退的速度（透過視網膜電圖ERG測量）。

視網膜色素變性 (RP) 市場—地理洞察

2025年，北美地區崛起成為重要的市場區域，佔據超過45.2%的市佔率。該地區受益於先進的醫療基礎設施、大量的研發投入以及視網膜疾病發病率的上升。美國食品藥物管理局（FDA）等監管機構的支持加快了創新療法的核准，促進了市場成長。人們對遺傳性疾病的日益關注以及對有效療法的需求，是推動市場擴張的主要動力。美國為主要貢獻者，其中Regeneron Pharmaceuticals和Spark Therapeutics等關鍵企業處於領先地位。加拿大也扮演著重要角色，專注於研發項目。生技公司與學術機構之間的合作構成了該地區競爭格局的特徵，從而拓展了新型療法的研發管線。大型製藥公司的存在確保了強勁的市場環境，促進了創新和藥物的可及性。

美國視網膜色素變性（RP）市場－國家概況

北美，尤其是美國和加拿大，以其許多大型企業（例如製藥公司）的集中而聞名，這些企業積極致力於開發新型療法以提供更好的治療。例如，2024年8月，專注於發現、開發和商業化新型基因和細胞療法及疫苗的生物技術公司Ocugen宣布，加拿大衛生部已簽發“無異議函”，允許其在加拿大啟動OCU400 III期臨床試驗。 OCU400是一種用於治療視網膜色素變性（RP）的修飾基因療法候選產品。這些企業專注於開發新型療法，這將促進區域市場成長。

視網膜色素變性（RP）市場競爭格局：

視網膜色素變性市場競爭激烈，涉及眾多利益相關者，包括製藥公司、生物技術公司、學術機構、研究組織和醫療服務提供者。這些機構參與的活動多種多樣，包括新療法的研發、現有療法的生產和商業化，以及為視網膜色素變性患者提供醫療服務。美國國立衛生研究院 (NIH) 和歐盟「地平線2020」計畫等政府機構為視網膜色素變性的研究和開發計畫提供資金和支持。這些機構在鼓勵創新、促進合作以及推進眼科領域的治療發現方面發揮著重要作用。

目錄

第1章：視網膜色素變性（RP）市場概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
    • 視網膜色素變性（RP）市場概況（依給藥途徑分類）
    • 按診斷分類的視網膜色素變性（RP）市場概況
    • 視網膜色素變性 (RP) 市場概況（按治療類型分類）
    • 視網膜色素變性 (RP) 市場概況（按疾病類型分類）
    • 視網膜色素變性（RP）市場概覽（按最終用戶分類）
    • 視網膜色素變性 (RP) 市場概況（按國家/地區分類）
    • 視網膜色素變性 (RP) 市場概況（按地區分類）
  • 競爭洞察

第3章：視網膜色素變性（RP）主要市場趨勢

  • 視網膜色素變性（RP）市場促進因素
    • 市場促進因素的影響分析
  • 視網膜色素變性（RP）市場限制
    • 市場限制因素的影響分析
  • 視網膜色素變性（RP）市場機會
  • 視網膜色素變性（RP）市場未來趨勢

第4章：視網膜色素變性（RP）產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：視網膜色素變性（RP）市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：視網膜色素變性（RP）市場概況

  • 2024年視網膜色素變性（RP）市佔率分析
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：視網膜色素變性（RP）市場－依給藥途徑分類

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 主題
    • 口服
    • 其他

第8章：視網膜色素變性（RP）市場－依診斷分類

  • 概述
    • 按診斷分類的細分市場佔有率分析
    • 視網膜電圖
    • 基因檢測
    • 視野檢查
    • 其他

第9章：視網膜色素變性（RP）市場－依治療類型分類

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 視網膜植入物
    • 維生素A補充劑
    • 鈣通道阻斷劑
    • 二十二碳六烯酸（DHA）
    • 基因療法
    • 其他

第10章：視網膜色素變性（RP）市場－依疾病類型分類

  • 概述
    • 按診斷分類的細分市場佔有率分析
    • 體染色體顯性遺傳
    • X連鎖視網膜色素變性
    • 體染色體隱性遺傳

第11章：視網膜色素變性（RP）市場－依終端使用者分類

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 居家照護
    • 專科診所
    • 其他

第12章：視網膜色素變性（RP）市場－依地域分類

  • 介紹
    • 按地域分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美視網膜色素變性（RP）主要生產商
    • 北美市場規模及預測（按國家/地區分類）
    • 北美市場規模及預測（依給藥途徑分類）
    • 北美市場規模及預測（依診斷分類）
    • 北美市場規模及預測（按治療類型分類）
    • 北美市場規模及預測（依疾病類型分類）
    • 北美市場規模及預測（依最終用戶分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲視網膜色素變性（RP）主要生產商
    • 歐洲市場規模及預測（按國家/地區分類）
    • 歐洲市場規模及預測（依給藥途徑分類）
    • 歐洲市場規模及預測（依診斷分類）
    • 歐洲市場規模及預測（依治療類型分類）
    • 歐洲市場規模及預測（依疾病類型分類）
    • 歐洲市場規模及預測（依最終用戶分類）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區
    • 概述
    • 亞太地區視網膜色素變性（RP）主要生產商
    • 亞太市場規模及預測（依國家/地區分類）
    • 亞太地區市場規模及預測（依給藥途徑分類）
    • 亞太地區市場規模及預測（依診斷分類）
    • 亞太地區市場規模及預測（依治療類型分類）
    • 亞太地區市場規模及預測（依疾病類型分類）
    • 亞太地區市場規模及預測（依最終用戶分類）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太其他地區
  • 拉丁美洲
    • 概述
    • 視網膜色素變性（RP）拉丁美洲主要生產商
    • 拉丁美洲市場規模及預測（按國家/地區分類）
    • 拉丁美洲市場規模及預測（依給藥途徑分類）
    • 拉丁美洲市場規模及預測（依診斷分類）
    • 拉丁美洲市場規模及預測（按治療類型分類）
    • 拉丁美洲市場規模及預測（依疾病類型分類）
    • 拉丁美洲市場規模及預測（按最終用戶分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 視網膜色素變性（RP）中東和非洲主要生產商
    • 中東和非洲市場規模及預測（按國家/地區分類）
    • 中東和非洲市場規模及預測（按給藥途徑分類）
    • 中東及非洲市場規模及預測（依診斷分類）
    • 中東和非洲市場規模及預測（按治療類型分類）
    • 中東和非洲市場規模及預測（按疾病類型分類）
    • 中東和非洲市場規模及預測（按最終用戶分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 中東和非洲其他地區

第13章：主要供應商分析－視網膜色素變性（RP）產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Bausch Health Companies Inc.
    • Novartis AG
    • Ionis Pharmaceuticals, Inc.
    • AGTC
    • MeiraGTx Limited
    • ReNeuron Group plc
    • ProQR Therapeutics
    • Sun Pharmaceutical Industries Ltd.
    • Allergan
    • Astellas Pharma Inc.
    • AstraZeneca
    • Caladrius Biosciences, Inc.
    • Genethon
    • Gensight Biologics
    • Johnson & Johnson Private Limited
    • Orphagen Pharmaceuticals, Inc
    • Clino Corporation
    • Spark Therapeutics, Inc
    • Grupo Ferrer International, SA
    • Nanovector Srl
    • Mimetogen Pharmaceuticals Inc.
    • Others

第14章：360度分析師視角

第15章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5749

The Retinitis Pigmentosa (RP) Market size was valued at US$ 14,789.90 Million in 2024, expanding at a CAGR of 7.4% from 2025 to 2032.

Retinitis Pigmentosa (RP) is a group of inherited retinal disorders that cause progressive vision loss by damaging the retina, the light-sensitive tissue in the back of the eye. Individuals with RP typically have reduced night vision, gradual peripheral vision loss, and, in the advanced stages, complete blindness. The RP market is primarily driven by improved diagnosis of inherited retinal diseases, increased access to genetic testing, and rapid advances in gene therapy, stem-cell therapy, and optogenetic approaches that allow for more targeted and personalized treatment options. However, market growth is limited by the high cost of gene therapies and the scarcity of approved treatments beyond Luxturna. Key market trends include increased investment in AAV- and CRISPR-based therapeutic platforms, as well as a greater emphasis on early genetic screening.

Retinitis Pigmentosa (RP) Market- Market Dynamics

Rising Healthcare Expenditure Drives Growth In The Retinitis Pigmentosa Market

The increase in healthcare expenditure is expected to drive future growth in the retinitis pigmentosa market. Healthcare expenditure is the total amount of money spent on healthcare goods and services, such as medical treatments, medications, hospitalizations, and preventive care, over a given time period, indicating the overall cost of healthcare provision within a population. Healthcare spending is increasing as the cost of advanced medical technologies rises, populations age, and chronic diseases become more prevalent. Healthcare spending for retinitis pigmentosa is concentrated on improving diagnostic methods, developing effective treatments, and providing supportive care to manage vision loss. For example, according to the National Institutes of Health, a US-based government agency, healthcare spending in the United States increased by 4.1% in 2022 to $4.5 trillion, representing a faster growth rate than the 3.2% increase observed in 2021. As a result, rising healthcare costs are fueling the growth of the retinitis pigmentosa industry.

Retinitis Pigmentosa (RP) Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Route of Administration, Diagnosis, Treatment Type, Disease Type, End-Users, and Region.

In treatment type segment, the gene therapy category is expected to remain a key growth driver throughout the forecast period. Gene therapy for retinitis pigmentosa focuses on delivering functional genes to patient cells to combat disease-causing mutations. Luxturna (voretigene neparvovec-rzyl) is the only FDA-approved therapy for biallelic RPE65 mutations, which restores functional gene expression in retinal cells. Beyond Luxturna, several candidates are making progress in clinical trials, utilizing AAV and other vector technologies to target a broader range of mutations. Continued investment from leading biopharmaceutical companies is boosting development activity and shaping the segment's upward trajectory. For instance, in May 2025, Beacon Therapeutics Holdings Limited reported 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company's lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP).

Based on Treatment Type segment, Vitamin A supplements remain an essential and historically significant segment of the RP market because vitamin A (specifically, retinol palmitate) has long been studied for its ability to slow photoreceptor degeneration in some RP patients. In the absence of broadly approved gene therapies (for many genetic subtypes), vitamin A has provided a relatively simple, low-tech supplement that may delay the decline in retinal function. Because RP is genetically heterogeneous, nutritional interventions such as vitamin A provide patients with a low-cost, scalable option, especially in settings where advanced therapies are unavailable or as a complementary measure. Vitamin A supplementation exemplifies how more traditional, non-gene-based treatments remain part of the therapeutic mix, even in a market dominated by sophisticated therapies. According to the NEI, a trial supported by the institute (1984-1992) discovered that taking 15,000 IU of vitamin A palmitate daily could slow the rate of functional retinal decline (measured using ERG).

Retinitis Pigmentosa (RP) Market- Geographical Insights

In 2025, North America emerged as a significant region, accounting for more than 45.2% of the market. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a rising incidence of retinal disease. Regulatory support from agencies such as the FDA expedites the approval of innovative therapies, resulting in market growth. The growing awareness of genetic disorders, as well as the demand for effective treatments, are driving this expansion. The United States is the primary contributor, with key players including Regeneron Pharmaceuticals and Spark Therapeutics leading the way. Canada also plays an important role, focusing on R&D initiatives. Collaborations between biotech firms and academic institutions characterize the competitive landscape, thereby expanding the pipeline of novel therapies. The presence of major pharmaceutical companies ensures a strong market environment that promotes innovation and accessibility.

United States Retinitis Pigmentosa (RP) Market- Country Insights

North America, particularly the United States, Canada is known for its large concentration of major players such as pharmaceutical companies, which actively pursue the development of novel therapies for better treatment. For instance, in August 2024, Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Health Canada has issued a "No Objection Letter" to begin the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy product candidate for retinitis pigmentosa (RP). These are focused on the development of novel therapeutics, which will boost regional market growth.

Retinitis Pigmentosa (RP) Market- Competitive Landscape:

The Retinitis Pigmentosa market is competitive, with a diverse range of stakeholders including pharmaceutical companies, biotechnology firms, academic institutions, research organizations, and healthcare providers. These organizations are involved in a variety of activities, including research and development of new therapies, manufacturing and commercialization of existing treatments, and providing healthcare services to retinitis pigmentosa patients. Government agencies, including the National Institutes of Health (NIH) in the United States and the European Commission's Horizon 2020 program, fund and support retinitis pigmentosa research and development initiatives. These organizations play an important role in encouraging innovation, facilitating collaborations, and advancing therapeutic discoveries in the field of ophthalmology.

Recent Developments:

In December 2024, Bausch + Lomb, a subsidiary of Bausch Health, has acquired Elios Vision Inc., the developer of the ELIOS system, a minimally invasive glaucoma surgery (MIGS) procedure that uses an excimer laser. This acquisition demonstrates Bausch + Lomb's commitment to providing advanced glaucoma treatment solutions, thereby improving patient care around the world.

In May, 2024, The EYE-RD Global Registry was introduced by Johnson & Johnson at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). This non-interventional global registry is the first of its kind and aims to collect longitudinal clinical data on patients with inherited retinal diseases (IRDs), such as X-linked retinitis pigmentosa. The registry's goal is to fill knowledge gaps by providing real-world insights into disease progression and patient experiences, which will aid in IRD research, diagnosis, and treatment strategies.

In August 2025, Novartis (CH) has announced a strategic collaboration with a leading biotechnology company to co-develop a novel gene therapy to treat Retinitis Pigmentosa. This collaboration is expected to leverage both companies' genetic research expertise, potentially shortening the development timeline and expanding the therapeutic options available to patients. Such collaborations not only strengthen Novartis' research capabilities, but also reflect an industry-wide trend toward collaborative innovation.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Bausch Health Companies Inc.
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • AGTC
  • MeiraGTx Limited
  • ReNeuron Group plc
  • ProQR Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Astellas Pharma Inc.
  • AstraZeneca
  • Caladrius Biosciences, Inc.
  • Genethon
  • Gensight Biologics
  • Johnson & Johnson Private Limited
  • Orphagen Pharmaceuticals, Inc
  • Clino Corporation
  • Spark Therapeutics, Inc
  • Grupo Ferrer International, S.A.
  • Nanovector S.r.l
  • Mimetogen Pharmaceuticals Inc.
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Topical
  • Oral
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2019 - 2032

  • Electroretinogram
  • Genetic Testing
  • Visual Field Testing
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Retinal Implants
  • Vitamin A Supplements
  • Calcium channel blockers
  • Docosahexaenoic acid (DHA)
  • Gene Therapy
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Autosomal Dominant
  • X-linked RP
  • Autosomal Recessive

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Retinitis Pigmentosa (RP) Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Retinitis Pigmentosa (RP) Market Snippet by Route of Administration
    • 2.1.2. Retinitis Pigmentosa (RP) Market Snippet by Diagnosis
    • 2.1.3. Retinitis Pigmentosa (RP) Market Snippet by Treatment Type
    • 2.1.4. Retinitis Pigmentosa (RP) Market Snippet by Disease Type
    • 2.1.5. Retinitis Pigmentosa (RP) Market Snippet by End-Users
    • 2.1.6. Retinitis Pigmentosa (RP) Market Snippet by Country
    • 2.1.7. Retinitis Pigmentosa (RP) Market Snippet by Region
  • 2.2. Competitive Insights

3. Retinitis Pigmentosa (RP) Key Market Trends

  • 3.1. Retinitis Pigmentosa (RP) Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Retinitis Pigmentosa (RP) Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Retinitis Pigmentosa (RP) Market Opportunities
  • 3.4. Retinitis Pigmentosa (RP) Market Future Trends

4. Retinitis Pigmentosa (RP) Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Retinitis Pigmentosa (RP) Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Retinitis Pigmentosa (RP) Market Landscape

  • 6.1. Retinitis Pigmentosa (RP) Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Retinitis Pigmentosa (RP) Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 7.1.2. Topical
    • 7.1.3. Oral
    • 7.1.4. Others

8. Retinitis Pigmentosa (RP) Market - By Diagnosis

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
    • 8.1.2. Electroretinogram
    • 8.1.3. Genetic Testing
    • 8.1.4. Visual Field Testing
    • 8.1.5. Others

9. Retinitis Pigmentosa (RP) Market - By Treatment Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 9.1.2. Retinal Implants
    • 9.1.3. Vitamin A Supplements
    • 9.1.4. Calcium channel blockers
    • 9.1.5. Docosahexaenoic acid (DHA)
    • 9.1.6. Gene Therapy
    • 9.1.7. Others

10. Retinitis Pigmentosa (RP) Market - By Disease Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
    • 10.1.2. Autosomal Dominant
    • 10.1.3. X-linked RP
    • 10.1.4. Autosomal Recessive

11. Retinitis Pigmentosa (RP) Market - By End-Users

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Homecare
    • 11.1.4. Specialty Clinics
    • 11.1.5. Others

12. Retinitis Pigmentosa (RP) Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Retinitis Pigmentosa (RP) Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Retinitis Pigmentosa (RP) Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Retinitis Pigmentosa (RP) Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Retinitis Pigmentosa (RP) Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Retinitis Pigmentosa (RP) Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Retinitis Pigmentosa (RP) Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Bausch Health Companies Inc.
    • 13.2.2. Novartis AG
    • 13.2.3. Ionis Pharmaceuticals, Inc.
    • 13.2.4. AGTC
    • 13.2.5. MeiraGTx Limited
    • 13.2.6. ReNeuron Group plc
    • 13.2.7. ProQR Therapeutics
    • 13.2.8. Sun Pharmaceutical Industries Ltd.
    • 13.2.9. Allergan
    • 13.2.10. Astellas Pharma Inc.
    • 13.2.11. AstraZeneca
    • 13.2.12. Caladrius Biosciences, Inc.
    • 13.2.13. Genethon
    • 13.2.14. Gensight Biologics
    • 13.2.15. Johnson & Johnson Private Limited
    • 13.2.16. Orphagen Pharmaceuticals, Inc
    • 13.2.17. Clino Corporation
    • 13.2.18. Spark Therapeutics, Inc
    • 13.2.19. Grupo Ferrer International, S.A.
    • 13.2.20. Nanovector S.r.l
    • 13.2.21. Mimetogen Pharmaceuticals Inc.
    • 13.2.22. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us